These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
588 related articles for article (PubMed ID: 31161857)
1. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation. Chen Y; Ernst P Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857 [TBL] [Abstract][Full Text] [Related]
2. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia. Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824 [TBL] [Abstract][Full Text] [Related]
3. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Heikamp EB; Henrich JA; Perner F; Wong EM; Hatton C; Wen Y; Barwe SP; Gopalakrishnapillai A; Xu H; Uckelmann HJ; Takao S; Kazansky Y; Pikman Y; McGeehan GM; Kolb EA; Kentsis A; Armstrong SA Blood; 2022 Feb; 139(6):894-906. PubMed ID: 34582559 [TBL] [Abstract][Full Text] [Related]
5. Murine Retrovirally-Transduced Bone Marrow Engraftment Models of MLL-Fusion-Driven Acute Myelogenous Leukemias (AML). Stubbs MC; Krivtsov AV Curr Protoc Pharmacol; 2017 Sep; 78():14.42.1-14.42.19. PubMed ID: 28892146 [TBL] [Abstract][Full Text] [Related]
6. MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome. Stavropoulou V; Kaspar S; Brault L; Sanders MA; Juge S; Morettini S; Tzankov A; Iacovino M; Lau IJ; Milne TA; Royo H; Kyba M; Valk PJM; Peters AHFM; Schwaller J Cancer Cell; 2016 Jul; 30(1):43-58. PubMed ID: 27344946 [TBL] [Abstract][Full Text] [Related]
7. Mouse models of MLL leukemia: recapitulating the human disease. Milne TA Blood; 2017 Apr; 129(16):2217-2223. PubMed ID: 28179274 [TBL] [Abstract][Full Text] [Related]
8. Tet1 is not required for myeloid leukemogenesis by MLL-ENL in novel mouse models. Ono R; Masuya M; Inoue N; Shinmei M; Ishii S; Maegawa Y; Maharjan BD; Katayama N; Nosaka T PLoS One; 2021; 16(3):e0248425. PubMed ID: 33705482 [TBL] [Abstract][Full Text] [Related]
9. Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia. Li BE; Ernst P Exp Hematol; 2014 Dec; 42(12):995-1012. PubMed ID: 25264566 [TBL] [Abstract][Full Text] [Related]
10. The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia. Serio J; Ropa J; Chen W; Mysliwski M; Saha N; Chen L; Wang J; Miao H; Cierpicki T; Grembecka J; Muntean AG Oncogene; 2018 Jan; 37(4):450-460. PubMed ID: 28945229 [TBL] [Abstract][Full Text] [Related]
11. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Arai S; Yoshimi A; Shimabe M; Ichikawa M; Nakagawa M; Imai Y; Goyama S; Kurokawa M Blood; 2011 Jun; 117(23):6304-14. PubMed ID: 21190993 [TBL] [Abstract][Full Text] [Related]
12. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Bindels EM; Havermans M; Lugthart S; Erpelinck C; Wocjtowicz E; Krivtsov AV; Rombouts E; Armstrong SA; Taskesen E; Haanstra JR; Beverloo HB; Döhner H; Hudson WA; Kersey JH; Delwel R; Kumar AR Blood; 2012 Jun; 119(24):5838-49. PubMed ID: 22553314 [TBL] [Abstract][Full Text] [Related]
13. MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia. Chen Y; Anastassiadis K; Kranz A; Stewart AF; Arndt K; Waskow C; Yokoyama A; Jones K; Neff T; Lee Y; Ernst P Cancer Cell; 2017 Jun; 31(6):755-770.e6. PubMed ID: 28609655 [TBL] [Abstract][Full Text] [Related]
14. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis. Zhang X; Zheng X; Yang H; Yan J; Fu X; Wei R; Xu X; Zhang Z; Yu A; Zhou K; Ding J; Geng M; Huang X Cancer Lett; 2018 Sep; 431():150-160. PubMed ID: 29857126 [TBL] [Abstract][Full Text] [Related]
15. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia. Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180 [TBL] [Abstract][Full Text] [Related]
16. Cell context in the control of self-renewal and proliferation regulated by MLL1. Artinger EL; Ernst P Cell Cycle; 2013 Sep; 12(18):2969-72. PubMed ID: 23974107 [TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction. Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859 [TBL] [Abstract][Full Text] [Related]
18. The histone methyltransferase activity of MLL1 is dispensable for hematopoiesis and leukemogenesis. Mishra BP; Zaffuto KM; Artinger EL; Org T; Mikkola HK; Cheng C; Djabali M; Ernst P Cell Rep; 2014 May; 7(4):1239-47. PubMed ID: 24813891 [TBL] [Abstract][Full Text] [Related]
19. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia. Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727 [TBL] [Abstract][Full Text] [Related]